Endometrial hyperplasia: current approaches to diagnosis and treatment. Literature review and own experience





endometrial hyperplasia, postmenopause, obesity, metabolic syndrome, immunohistochemical markers, proliferation, apoptosis


Purpose of the study: to examine the morphological and immunohistochemical features of the endometrium in postmenopausal women with uterine bleeding, depending on body weight and metabolic syndrome.
Materials and methods. The study included 114 women with postmenopausal uterine bleeding. Women were divided into 3 groups. Group I included 41 patients with overweight and obesity class I–II, group II – 43 women with metabolic syndrome, group III (control) consisted of 30 patients with normal body weight. Hysteroscopy with morphological analysis of biopsied material was performed for all patients of groups I and III and 41 patients of group II. Pathohistological and immunohistochemical analysis were used to diagnose endometrial pathology. The level of cell proliferation in the endometrium was assessed by immunohistochemical analysis using monoclonal antibodies for Ki-67 expression; antiapoptotic activity was determined by the Bcl-2 and COX-2 expression.
Results. Endometrial pathology was diagnosed in 94.74% of women. Endometrial polyps in the structure of the identified pathologyprevailed in group I and control group III (82.93% and 83.33%, respectively), while endometrial polyps were detected in 25.59% of women in the group II. Endometrial hyperplasia was diagnosed in the vast majority (69.76%) in group II, hyperplasia without atypia was detected in 51.16% and endometrial hyperplasia with atypia in 18.60%.
Conclusions. Endometrial hyperplasia value was higher in postmenopausal women with metabolic syndrome compared to patients with normal weight, overweight and obesity. There was an increase of Ki-67, Bcl-2 and COX-2 expression in the endometrial glands in women with metabolic syndrome in comparison to patients with normal weight and obesity, for which only increased Bcl-2 expression in the stroma was observed. This confirms the existing data on the predominance of the apoptosis inhibition over proliferation in the formation of endometrial diseases in the postmenopausal period and confirms the combination of hyperproliferative processes and apoptosis inhibition if there is metabolic syndrome.

Author Biographies

T.F. Tatarchuk, NAMS of Ukraine; SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”; State Scientific Institution “CIMT of the NAS of Ukraine”

MD, professor, corresponding member of the NAMS of Ukraine;

deputy director for research work, head of the Endocrine Gynecology Department;

chief researcher, Department of Reproductive Health

Y.O. Dubossarska, Dnipro State Medical University

MD, professor, head of the Obstetrics, Gynecology and Perinatology Department, Faculty of Postgraduate Education

Z.M. Dubossarska, Dnipro State Medical University

MD, professor, Department of Family Medicine, Faculty of Postgraduate Education

S.I. Regeda, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”; SSI “CIMT of the NAS of Ukraine”

PhD, senior researcher, Endocrine Gynecology Department;

head of the Gynecology Department

O.V. Zanko, SSI “CIMT of the NAS of Ukraine”

PhD, researcher, Department of Reproductive Health


  1. Cancer in Ukraine, 2018–2019. Morbidity, mortality, indicators of oncology service activity. Kyiv (2020). Available from: [http://www.ncru.inf.ua/publications/BULL_21/index.htm].
  2. Auclair, M.-H., Yong, P.J., Salvador, S., et al. “Society of Gynecologic Oncology of Canada Guideline No. 390. Classification and Management of Endometrial Hyperplasia.” J Obstet Gynaecol Can 41.12 (2019): 1789–1800. DOI: 10.1016/j.jogc.2019.03.025
  3. Gallos, I.D., Alazzam, M., Clark, T.J., et al. Royal College of Obstetricians and Gynaecologists. Green-top № 67. Management of Endometrial Hyperplasia (2016). Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf
  4. Renaud, M.-C., Le, T. “SOGC Clinical Practice Guidelines No. 291. Epidemiology and Investigations for Suspected Endometrial Cancer.” Journal of Obstetrics and Gynaecology Canada 40.9 (2018): e703–e711. DOI: 10.1016/j.jogc.2018.07.005
  5. Cherniaeva, A.O., Mykytiuk, M.R., Karachentsev, Y.I., Kravchun, N.O. “The level of uricemia in patients with diabetes and anthropometric indices: clinical and biochemical correlations.” Problems of endocrine pathology 2 (2019): 73–80. DOI: 10.21856/j-PEP.2019.2.11
  6. Smith, R.A., von Eschenbach, A.C., Wender, R., et al. “American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers”. CA Cancer J Clin 51 (2001): 38.
  7. Setiawan, V.W., Yang, H.P., Pike, M.C., et al. “Type I and II endometrial cancers: have they different risk factors?” J Clin Oncol 31 (2013): 2607.
  8. American College of Obstetricians and Gynecologists. “ACOG Committee Opinion No. 793. Hereditary cancer syndromes and risk assessment.” Obstet Gynecol 134 (2019): e143–9.
  9. Reed, S.D., Urban, R.R. “Classification and diagnosis of endometrial hyperplasia.” Available from: [https://www. uptodate.com/contents/classification-and-diagnosis-of-endometrial-hyperplasia].
  10. American College of Obstetricians and Gynecologists. “ACOG Committee Opinion № 800. The use of hysteroscopy for the diagnosis and treatment of intrauterine pathology.” Obstet Gynecol 135 (2020): e138–48.
  11. Leone, F., Timmerman, D., Bourne, T., et al. “Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group.” Ultrasound Obstet Gynecol 35 (2010): 103–112. DOI: 10.1002/uog.7487
  12. American College of Obstetricians and Gynecologists. “ACOG Committee Opinion No. 734. The role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding.” Obstet Gynecol 131 (2018): e124–9.
  13. Society of Gynecologic Oncology, American College of Obstetricians and Gynecologists. “ACOG Committee Opinion No. 631. Endometrial Intraepithelial Neoplasia (Reaffirmed 2019).” Obstet Gynecol 125 (2015): 1272–8.
  14. Wolfman, W. “Reaffirmed SOGC Clinical Practice Guidelines No. 249. Asymptomatic Endometrial Thickening.” J Obstet Gynaecol Can 40.5 (2018): e367–e377. DOI: 10.1016/j.jogc.2018.03.005
  15. Kanzaki, H. Uterine Endometrial Function. Springer, 2016.
  16. Kalugina, L.V., Tatarchuk, Т. F. “Polycystic ovary syndrome: approach to correction of metabolic disorders.” Reproductive Endocrinology 2.52 (2020): 54–60. DOI: 10.18370/2309-4117.2020.52.54-60
  17. Troncon, J.K., Meola, J., Candido-dos-Reis, F.J., et al. “Analysis of differential genetic expression in endometrial polyps of postmenopausal women.” Climacteric 20.5 (2017): 462–6. DOI: 10.1080/13697137.2017.1335701
  18. Zanko, O.V. Diagnosis, treatment and prevention of hyperproliferative diseases of the endometrium in postmenopausal women. Thesis abstract for PhD degree. Kyiv (2018).
  19. Pereira, A.K.C., Garcia, M.T., Pinheiro, W., et al. “What is the influence of cyclooxygenase-2 on postmenopausal endometrial polyps?” Climacteric 18.4 (2014): 498–502. DOI: 10.3109/13697137.2014.966240
  20. Pinheiro, A., Antunes А., Andrade, L., et al. “Expression of hormone receptors, Bcl-2, Cox-2 and Ki67 in benign endometrial polyps and their association with obesity.” Molecular Medicine Reports 9.6 (2014): 2335–41. DOI: 10.3892/Mmr.2014.2125
  21. Saraiva, A.L.R., Payan-Carreira, F., Gärtner, I., et al. “Immunohistochemical expression of cyclooxygenase-2 (COX- 2) in feline endometrial adenocarcinoma and in normal and hyperplastic endometria.” Reproduction in Domestic Animals 50.2 (2015): 333–40. DOI: 10.1111/rda.12497
  22. Sanderson, P.A., Critchley, H.O.D., et al. “New concepts for an old problem: the diagnosis of endometrial hyperplasia.” Human Reproduction Update 23 (2017): 232–54. DOI: 10.1093/humupd/dmw042
  23. Jacobs, I., Gentry-Maharaj, A., Burnell, M., et al. “Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort.” Lancet Oncol 12 (2011): 38–48.
  24. Furness, S., Roberts, H., Marjoribanks, J., et al. “Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.” Cochrane Database Syst Rev 8 (2012): CD000402.
  25. Royal College of Obstetricians and Gynaecologists. Long-term Consequences of Polycystic Ovary Syndrome. Green-top Guideline No. 33. London. RCOG (2014).
  26. Antypkin, Y.G., Vdovychenko, Y.P., Graziottin, A., et al. “Uterine bleeding and quality of life of a woman. Resolution of the expert council.” Reproductive Endocrinology 3.47 (2019): 8–12. DOI: 10.18370/2309-4117.2019.47.8-12
  27. Argenta, P.A., Kassing, M., Truskinovsky, A.M., et al. “Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women: a prospective, pilot study.” BJOG 120 (2013): 795–800.
  28. Modesitt, S.C., Hallowell, P.T., Slack-Davis, J.K., et al. “Women at extreme risk for obesity-related carcinogenesis: Baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life.” Gynecol Oncol 138 (2015): 238–45.
  29. Jernigan, A.M., Maurer, K.A., Cooper, K., et al. “Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists: a prospective cohort study.” Am J Obstet Gynecol 213 (2015): 350.e1–10.
  30. Royal College of Obstetricians and Gynaecologists, British Society of Gynaecological Endoscopy. Management of Suspected Ovarian Masses in Premenopausal Women. Green-top Guideline No. 62. London. RCOG (2011).
  31. Gallos, I.D., Krishan, P., Shehmar, M., et al. “LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.” Hum Reprod 28 (2013): 2966–71.
  32. Ismail, M.T., Fahmy, D.M., Elshmaa, N.S. “Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia.” Reprod Sci 20 (2013): 45–50.
  33. Behnamfar, F., Ghahiri, A., Tavakoli, M. “Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia.” J Res Med Sci 19 (2014): 686–90.
  34. Gallos, I.D., Yap, J., Rajkhowa, M., et al. “Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis.” Am J Obstet Gynecol 207 (2012): 266.e1–12.
  35. National Institute for Health and Care Excellence. Fertility problems: assessment and treatment. NICE clinical guideline 156. Manchester. NICE (2013).
  36. Emons, G., Beckmann, M.W., Schmidt, D., et al. “New WHO classification of endometrial hyperplasias.” Geburtshilfe Frauenheilkd 75 (2015): 135–6.
  37. Zaino, R., Carinelli, S.G., Ellenson, L.H., et al. WHO Classification of Tumours of Female Reproductive Organs. 4th edition ed. Lyon, France. WHO Press (2014).
  38. Beavis, A.L., Cheema, S., Holschneider, C.H., et al. “Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk.” Gynecol Oncol Rep 13 (2015): 71–5.
  39. Gunderson, C.C., Fader, A.N., Carson, K.A., et al. “Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.” Gynecol Oncol 125 (2012): 477–82.
  40. Armstrong, A.J., Hurd, W.W., Elguero, S., et al. “Diagnosis and management of endometrial hyperplasia.” J Minim Invasive Gynecol 19 (2012): 562–71.
  41. Shan, W., Wang, C., Zhang, Z., et al. “Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.” J Gynecol Oncol 25 (2014): 214–20.
  42. Mitsuhashi, A., Sato, Y., Kiyokawa, T., et al. “Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.” Ann Oncol 27 (2016): 262–6.
  43. Ørbo, A., Arnes, M., Vereide, A.B., et al. “Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.” BJOG 123 (2016): 1512–9.
  44. Gonthier, C., Piel, B., Touboul, C., et al. “Cancer incidence in patients with atypical endometrial hyperplasia managed by primary hysterectomy or fertility-sparing treatment.” Anticancer Res 35 (2015): 6799–804.
  45. Tatarchuk, T.F., Kalugina, L.V., Tutchenko, T.N.“Endometrial hyperplastic processes: what's new?” Reproductive endocrinology 5 (2015): 7–13. DOI: 10.18370/2309-4117.2015.25.7-13



How to Cite

Tatarchuk, T., Dubossarska, Y., Dubossarska, Z., Regeda, S., & Zanko, O. (2021). Endometrial hyperplasia: current approaches to diagnosis and treatment. Literature review and own experience. REPRODUCTIVE ENDOCRINOLOGY, (58), 18–27. https://doi.org/10.18370/2309-4117.2021.58.18-27